Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag U.S. cancer centers slowly adopt subcutaneous immunotherapy due to billing risks, despite patient and staff benefits.

flag Cancer centers are cautiously adopting subcutaneous immune checkpoint inhibitors, prioritizing stable reimbursement through permanent J-codes over rapid rollout despite patient and staff benefits. flag While these formulations improve convenience, reduce infusion times, and lower costs by eliminating IV supplies, institutions delay full implementation due to billing uncertainties and financial risks tied to high-cost drugs like pembrolizumab. flag Flexible prescribing models allow select patient switches, and some systems streamline adoption via electronic medical record updates. flag Future challenges include the Inflation Reduction Act’s 2028 pricing rules and biosimilar IV drugs, which may complicate long-term strategy. flag Despite nursing concerns over manual injection demands, growing use is supported by patient satisfaction and operational gains.

3 Articles